CYPRO-VITA Price

Overview

Welcome to Dwaey, specifically on CYPRO-VITA page.
This medicine contains an important and useful components, as it consists of
Cyproheptadine, Vit A, D, C, B1, B2, B6, B12, Niacinamideis available in the market in concentration

Name

Follitropin Alfa

Precaution

Before starting **Follitropin Alfa**, patients should consult with their healthcare provider due to the following precautions: - **Ovarian Hyperstimulation Syndrome (OHSS)**: **Follitropin Alfa** can lead to **OHSS**, a potentially life-threatening condition where the ovaries become swollen and painful. Women should be monitored closely, especially during the early stages of treatment. Symptoms of **OHSS** include abdominal pain, bloating, nausea, and vomiting. Immediate medical attention is necessary if these symptoms occur. - **Multiple Pregnancies**: **Follitropin Alfa** increases the likelihood of multiple pregnancies (twins, triplets, etc.), which can increase the risks for both the mother and the babies. Patients should be informed of the potential for multiple pregnancies and undergo regular monitoring. - **Ovarian Cysts**: Patients with **ovarian cysts** should be carefully evaluated before using **Follitropin Alfa**, as it may exacerbate existing conditions. **Follitropin Alfa** should not be used in women with **primary ovarian failure** or in cases of **abnormal uterine bleeding** where the cause is unclear. - **Liver and Kidney Disease**: **Follitropin Alfa** should be used with caution in patients with significant **liver** or **kidney disease**. Liver and renal function should be assessed before starting therapy, and the response to treatment should be monitored closely. - **Pregnancy**: **Follitropin Alfa** should not be used during **pregnancy**, as its safety in pregnant women has not been established. It is only used for **fertility treatments**, and women should avoid pregnancy during treatment. - **Multiple Previous IVF Failures**: Women with **repeated unsuccessful in vitro fertilization (IVF)** attempts should be monitored carefully, as **Follitropin Alfa** might lead to **ovarian overstimulation** or other complications in these patients.

Indication

**Follitropin Alfa** is primarily indicated for the following: - **Female Infertility Treatment**: **Follitropin Alfa** is used for **ovarian stimulation** in women who are undergoing **assisted reproductive technologies** (ART) such as **in vitro fertilization (IVF)** or **intracytoplasmic sperm injection (ICSI)**. It is used to stimulate the ovaries to produce multiple follicles, which increases the chances of egg retrieval. - **Hypogonadotropic Hypogonadism**: It is also used in women with **hypogonadotropic hypogonadism** (a condition where the body does not produce enough gonadotropins) to induce **ovulation**. This treatment is commonly prescribed for women who do not ovulate due to **hormonal imbalances**. - **Male Infertility**: In certain cases, **Follitropin Alfa** can be used in **men with hypogonadotropic hypogonadism** to stimulate the production of **sperm** and improve fertility.

Contra indication

**Follitropin Alfa** should not be used in the following situations: - **Primary Ovarian Failure**: **Follitropin Alfa** should not be used in women who have **primary ovarian failure** (i.e., when the ovaries do not respond to gonadotropins). - **Pregnancy**: It is contraindicated in **pregnant women**, as its use has not been studied in this population, and the effects on fetal development are not known. - **Uncontrolled Thyroid and Adrenal Disorders**: Women with **untreated thyroid** or **adrenal gland disorders** should avoid **Follitropin Alfa** because these conditions may interfere with the effectiveness of the medication or exacerbate complications. - **Abnormal Uterine Bleeding**: **Follitropin Alfa** is contraindicated in patients with abnormal **uterine bleeding** when the cause is unknown, as it may worsen the underlying condition. - **Ovarian Cysts or Enlarged Ovaries**: Women with **ovarian cysts** or **enlarged ovaries** should not use **Follitropin Alfa**, as the medication may worsen these conditions.

Side Effect

The side effects of **Follitropin Alfa** can range from mild to severe and include: - **Common Side Effects**: - **Ovarian Hyperstimulation Syndrome (OHSS)**: This is one of the most significant risks associated with **Follitropin Alfa** and can cause symptoms like **abdominal pain**, **nausea**, **vomiting**, and **bloating**. - **Injection Site Reactions**: These include **pain**, **redness**, **swelling**, or **bruising** at the site where the injection is administered. - **Headache**: Some patients report headaches as a common side effect. - **Mood Swings**: Hormonal changes may lead to mood changes, including **irritability** and **anxiety**. - **Fatigue**: Some women may feel more tired than usual during treatment with **Follitropin Alfa**. - **Severe Side Effects**: - **Ovarian Cysts or Enlarged Ovaries**: The treatment can cause the ovaries to become excessively enlarged, which can lead to discomfort and other complications. - **Multiple Pregnancies**: **Follitropin Alfa** increases the likelihood of **multiple pregnancies**, which carry increased risks for both the mother and the babies, such as **preterm birth**, **gestational diabetes**, and **hypertension**. - **Ectopic Pregnancy**: There is an increased risk of **ectopic pregnancy** (when the fertilized egg implants outside the uterus) due to the higher likelihood of multiple pregnancies. - **Ovarian Torsion**: Rarely, **Follitropin Alfa** can cause **ovarian torsion**, where the ovary twists, leading to **severe abdominal pain** and potential ovarian damage.

Pregnancy Category ID

5

Mode of Action

**Follitropin Alfa** is a **recombinant** form of **human follicle-stimulating hormone (FSH)**, a hormone involved in the development of eggs (oocytes) in women and sperm production in men. **FSH** stimulates the **follicles** in the ovaries to mature and produce eggs. In women, **Follitropin Alfa** works by stimulating **ovarian follicles** to grow and mature, which is necessary for **ovulation** and successful fertilization. The drug also plays a role in **sperm production** in men with certain types of infertility. By mimicking natural **FSH**, **Follitropin Alfa** helps promote ovarian and follicular development during **fertility treatments** like **in vitro fertilization (IVF)** and **intrauterine insemination (IUI)**.

Interaction

**Follitropin Alfa** may interact with certain drugs or substances, potentially altering its effects or causing side effects: - **Other Fertility Drugs**: Caution is advised when combining **Follitropin Alfa** with other fertility medications, as it may increase the risk of **ovarian hyperstimulation syndrome (OHSS)** or other complications related to excessive ovarian stimulation. - **Corticosteroids**: If used with **corticosteroids**, **Follitropin Alfa** may increase the risk of **fluid retention**, which can worsen **OHSS** or lead to other complications such as **high blood pressure**. - **Thyroid Hormone Therapy**: **Follitropin Alfa** may interact with **thyroid hormone therapy**, potentially altering the effectiveness of both treatments. Thyroid function should be monitored closely during treatment. - **Anticoagulants**: **Follitropin Alfa** may increase the risk of **bleeding** in patients who are on **anticoagulants**, so blood clotting should be monitored regularly.

Pregnancy Category Note

Information not available

Adult Dose

For **female infertility treatment**, the standard dosing regimen is: - **For Ovulation Induction**: **Follitropin Alfa** is typically administered as **subcutaneous injections**. The usual dose is **75 IU per day**, beginning on **day 2 or 3** of the menstrual cycle and continuing until an adequate response is achieved (usually 7–14 days). Doses may be adjusted based on the ovarian response as determined by **ultrasound** or **serum estrogen levels**. - **For Assisted Reproductive Technology (ART)**: In patients undergoing **in vitro fertilization (IVF)** or **intracytoplasmic sperm injection (ICSI)**, the typical starting dose is **150 IU per day**, and it is adjusted based on ovarian response.

Child Dose

**Follitropin Alfa** is not approved for use in children, as it is primarily used for **adult infertility treatment**. Its safety and efficacy in pediatric populations have not been established. As always, patients should consult their healthcare provider for the correct dosing and monitoring when starting **Follitropin Alfa** to ensure safe and effective use.

Renal Dose

**Follitropin Alfa** has not been specifically studied in patients with **renal impairment**. Therefore, caution is advised when using **Follitropin Alfa** in patients with **kidney disease**. Kidney function should be monitored regularly, and the dose may need to be adjusted accordingly.

Administration

Information not available